Actos Patent Expiry Fuels Takeda’s Drive For Deals – Licensing Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
During BIO-Asia 2007 in Tokyo, Takeda’s head of licensing outlines the strategy behind the company’s deal with Affymax.
You may also be interested in...
Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head
But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.
Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy
Japanese firm simultaneously announces that it has inked a monoclonal antibody discovery deal with Xoma.
Generic Firms Must Pay Actos Legal Fees, Partly Because Of Claim Flip-Flops
In deciding for Takeda, judge says Mylan and Alphapharm also disregarded court orders and used faulty witnesses during their patent challenges.